Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice

Michael S. Boosalis, Jose I. Sangerman, Gary L. White, Roman F. Wolf, Ling Shen, Yan Dai, Emily White, Levi H Makala, Biaoru Li, Betty Sue Pace, Mehdi Nouraie, Douglas V. Faller, Susan P. Perrine

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

High-level fetal (γ) globin expression ameliorates clinical severity of the beta (β) hemoglobinopathies, and safe, orally-bioavailable γ-globin inducing agents would benefit many patients. We adapted a LCR-γ-globin promoter-GFP reporter assay to a high-throughput robotic system to evaluate five diverse chemical libraries for this activity. Multiple structurally- And functionally-diverse compounds were identified which activate the γ-globin gene promoter at nanomolar concentrations, including some therapeutics approved for other conditions. Three candidates with established safety profiles were further evaluated in erythroid progenitors, anemic baboons and transgenic mice, with significant induction of γ-globin expression observed in vivo. A lead candidate, Benserazide, emerged which demonstrated > 20-fold induction of γ-globin mRNA expression in anemic baboons and increased F-cell proportions by 3.5-fold in transgenic mice. Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa. These studies confirm the utility of high-throughput screening and identify previously unrecognized fetal globin inducing candidates which can be developed expediently for treatment of hemoglobinopathies.

Original languageEnglish (US)
Article number0144660
JournalPloS one
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Globins
Papio
Transgenic Mice
Screening
promoter regions
Throughput
genetically modified organisms
screening
L-dopa
mice
Benserazide
Hemoglobinopathies
therapeutics
amino acids
assays
Small Molecule Libraries
genes
cells
Carboxy-Lyases
Robotics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Boosalis, M. S., Sangerman, J. I., White, G. L., Wolf, R. F., Shen, L., Dai, Y., ... Perrine, S. P. (2015). Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice. PloS one, 10(12), [0144660]. https://doi.org/10.1371/journal.pone.0144660

Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice. / Boosalis, Michael S.; Sangerman, Jose I.; White, Gary L.; Wolf, Roman F.; Shen, Ling; Dai, Yan; White, Emily; Makala, Levi H; Li, Biaoru; Pace, Betty Sue; Nouraie, Mehdi; Faller, Douglas V.; Perrine, Susan P.

In: PloS one, Vol. 10, No. 12, 0144660, 01.12.2015.

Research output: Contribution to journalArticle

Boosalis, MS, Sangerman, JI, White, GL, Wolf, RF, Shen, L, Dai, Y, White, E, Makala, LH, Li, B, Pace, BS, Nouraie, M, Faller, DV & Perrine, SP 2015, 'Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice', PloS one, vol. 10, no. 12, 0144660. https://doi.org/10.1371/journal.pone.0144660
Boosalis, Michael S. ; Sangerman, Jose I. ; White, Gary L. ; Wolf, Roman F. ; Shen, Ling ; Dai, Yan ; White, Emily ; Makala, Levi H ; Li, Biaoru ; Pace, Betty Sue ; Nouraie, Mehdi ; Faller, Douglas V. ; Perrine, Susan P. / Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice. In: PloS one. 2015 ; Vol. 10, No. 12.
@article{386019e292d9412197fcd61bdaa4243b,
title = "Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice",
abstract = "High-level fetal (γ) globin expression ameliorates clinical severity of the beta (β) hemoglobinopathies, and safe, orally-bioavailable γ-globin inducing agents would benefit many patients. We adapted a LCR-γ-globin promoter-GFP reporter assay to a high-throughput robotic system to evaluate five diverse chemical libraries for this activity. Multiple structurally- And functionally-diverse compounds were identified which activate the γ-globin gene promoter at nanomolar concentrations, including some therapeutics approved for other conditions. Three candidates with established safety profiles were further evaluated in erythroid progenitors, anemic baboons and transgenic mice, with significant induction of γ-globin expression observed in vivo. A lead candidate, Benserazide, emerged which demonstrated > 20-fold induction of γ-globin mRNA expression in anemic baboons and increased F-cell proportions by 3.5-fold in transgenic mice. Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa. These studies confirm the utility of high-throughput screening and identify previously unrecognized fetal globin inducing candidates which can be developed expediently for treatment of hemoglobinopathies.",
author = "Boosalis, {Michael S.} and Sangerman, {Jose I.} and White, {Gary L.} and Wolf, {Roman F.} and Ling Shen and Yan Dai and Emily White and Makala, {Levi H} and Biaoru Li and Pace, {Betty Sue} and Mehdi Nouraie and Faller, {Douglas V.} and Perrine, {Susan P.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0144660",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice

AU - Boosalis, Michael S.

AU - Sangerman, Jose I.

AU - White, Gary L.

AU - Wolf, Roman F.

AU - Shen, Ling

AU - Dai, Yan

AU - White, Emily

AU - Makala, Levi H

AU - Li, Biaoru

AU - Pace, Betty Sue

AU - Nouraie, Mehdi

AU - Faller, Douglas V.

AU - Perrine, Susan P.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - High-level fetal (γ) globin expression ameliorates clinical severity of the beta (β) hemoglobinopathies, and safe, orally-bioavailable γ-globin inducing agents would benefit many patients. We adapted a LCR-γ-globin promoter-GFP reporter assay to a high-throughput robotic system to evaluate five diverse chemical libraries for this activity. Multiple structurally- And functionally-diverse compounds were identified which activate the γ-globin gene promoter at nanomolar concentrations, including some therapeutics approved for other conditions. Three candidates with established safety profiles were further evaluated in erythroid progenitors, anemic baboons and transgenic mice, with significant induction of γ-globin expression observed in vivo. A lead candidate, Benserazide, emerged which demonstrated > 20-fold induction of γ-globin mRNA expression in anemic baboons and increased F-cell proportions by 3.5-fold in transgenic mice. Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa. These studies confirm the utility of high-throughput screening and identify previously unrecognized fetal globin inducing candidates which can be developed expediently for treatment of hemoglobinopathies.

AB - High-level fetal (γ) globin expression ameliorates clinical severity of the beta (β) hemoglobinopathies, and safe, orally-bioavailable γ-globin inducing agents would benefit many patients. We adapted a LCR-γ-globin promoter-GFP reporter assay to a high-throughput robotic system to evaluate five diverse chemical libraries for this activity. Multiple structurally- And functionally-diverse compounds were identified which activate the γ-globin gene promoter at nanomolar concentrations, including some therapeutics approved for other conditions. Three candidates with established safety profiles were further evaluated in erythroid progenitors, anemic baboons and transgenic mice, with significant induction of γ-globin expression observed in vivo. A lead candidate, Benserazide, emerged which demonstrated > 20-fold induction of γ-globin mRNA expression in anemic baboons and increased F-cell proportions by 3.5-fold in transgenic mice. Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa. These studies confirm the utility of high-throughput screening and identify previously unrecognized fetal globin inducing candidates which can be developed expediently for treatment of hemoglobinopathies.

UR - http://www.scopus.com/inward/record.url?scp=84958074472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958074472&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0144660

DO - 10.1371/journal.pone.0144660

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - 0144660

ER -